Clinical investigations on a wide variety of tumor types have shown a significant correlation between PD-1/PD-L1 inhibitor effectiveness and the TMB in PD-L1-positive populations, indicating that the TMB may be a suitable biomarker for predicting PD-1/PD-L1 drug efficacy [84,85]. This evidence concerns the gene PDCD1 and neoplasm.